InterShunt Technologies has announced the start of the EASE HF2 early feasibility study, which is evaluating a device designed to reduce heart failure symptoms and improve quality of life.
The first US procedure utilising InterShunt’s technology was performed by Sitaramesh Emani and the Structural Heart Intervention team at The Christ Hospital Health Network (Cincinnati, USA).
“We’re excited to get this study started,” said Emani. “The first procedure went smoothly, and the patient went home the next day feeling well. It’s an encouraging start, and we’re hopeful this treatment can help many more people.”
The study focuses on patients with heart failure with reduced ejection fraction (HFrEF). The device works by creating a small opening between the heart’s upper chambers to relieve pressure that builds up in heart failure. It uses a mechanical cutting method that avoids scarring and allows the heart to move naturally.
“This first enrolment is a big step for our team and for people living with heart failure. We are incredibly thankful to the patient, their family, and the team at The Christ Hospital for making this possible,” said Harlee Sorkin, CEO of InterShunt Technologies. “Because the procedure leaves nothing behind in the heart, it avoids the risks of permanent implants and keeps future treatment options open.”
